LCTX
HEALTHCARELineage Cell Therapeutics Inc
$1.43-0.03 (-2.05%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving LCTX Today?
No stock-specific AI insight has been generated for LCTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.44$2.09
$1.43
Fundamentals
Market Cap$364M
P/E Ratio—
EPS$-0.28
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume806K
Avg Volume (10D)—
Shares Outstanding249.3M
LCTX News
21 articles- Guardant Health (GH) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026Yahoo Finance·May 5, 2026
- OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026Yahoo Finance·May 4, 2026
- Niagen Bioscience And 2 Additional Promising Penny Stocks For Your ConsiderationYahoo Finance·Apr 15, 2026
- Lineage Announces Formation of Scientific Advisory BoardYahoo Finance·Apr 13, 2026
- Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsBenzinga·Apr 10, 2026
- Lineage Cell (LCTX) Launches Its Latest Cell Therapy ProgramYahoo Finance·Mar 31, 2026
- Lineage Launches New Cell Therapy Program in Corneal Endothelial DiseaseYahoo Finance·Mar 24, 2026
- Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- Lineage Cell Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Lineage Cell (LCTX) Reports Break-Even Earnings for Q4Yahoo Finance·Mar 5, 2026
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 5, 2026
- Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 3, 2026
- Pacira (PCRX) Lags Q4 Earnings and Revenue EstimatesYahoo Finance·Feb 26, 2026
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026Yahoo Finance·Feb 26, 2026
- trivago Leads The Pack Of 3 Promising Penny StocksYahoo Finance·Feb 4, 2026
- NeoVolta Leads The Charge With These 3 Penny Stock ContendersYahoo Finance·Jan 6, 2026
- Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor BioscienceYahoo Finance·Jan 6, 2026
- Lineage Cell Therapeutics Issues Letter to StockholdersYahoo Finance·Jan 5, 2026
- 3 Promising Penny Stocks With Market Caps Below $800MYahoo Finance·Dec 8, 2025
- Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsightYahoo Finance·Nov 17, 2025
All 21 articles loaded
Price Data
Open$1.46
Previous Close$1.46
Day High$1.50
Day Low$1.45
52 Week High$2.09
52 Week Low$0.44
52-Week Range
$0.44$2.09
$1.43
Fundamentals
Market Cap$364M
P/E Ratio—
EPS$-0.28
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume806K
Avg Volume (10D)—
Shares Outstanding249.3M
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—